Company Overview and News

Mark Benadiba and Ben Knight Join Tinley’s Advisory Board

2018-05-16 globenewswire
SANTA MONICA, Calif. and TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- The Tinley Beverage Company Inc. (the “Company" or "Tinley") (CSE:TNY) (OTCQX:TNYBF) is pleased to announce that long-time Cott Board and Executive member Mark Benadiba, and California cannabis industry leader Ben Knight have joined the Company’s advisory board.

COT / Cott Corp. FORM 10-Q (Quarterly Report)

Form 10-Q Table of Contents United States Securities and Exchange Commission Washington, D.C.

COT / Cott Corp. S-8

S-8 As filed with the Securities and Exchange Commission on May 9, 2018 Registration No. 333-

Pilgrim's Pride (PPC) to Report Q1 Earnings: What to Expect?

2018-05-09 zacks
Pilgrim's Pride Corporation (PPC - Free Report) is scheduled to report first-quarter 2018 results on Apr 10, after the market closes. The company reported better-than-expected results in three of the last four quarters, while lagging in one. Average earnings surprise was a positive 8.62%. Notably, in the last reported quarter, the company’s earnings of 58 cents per share surpassed the Zacks Consensus Estimate by 9.

The Green Organic Dutchman Assembles World Class Senior Leadership Team

2018-05-07 globenewswire
TORONTO, May 07, 2018 (GLOBE NEWSWIRE) -- The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) is pleased to announce the addition of several key executives including CFO, General Counsel, VP of Sales, VP of Marketing, VP of Operations, and Regional Sales Manager for Ontario and Western Canada.

COT / Cott Corp. FORM 8-K (Current Report)


COT / Cott Corp. 8-A12B


Cott (Canada) (COT) Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Welcome to Cott Corporation's First Quarter 2018 Earnings Conference Call. All participants are currently in listen-only mode. This call will end no later than 11:00 am Eastern time. This call is being webcast live on Cott's website at and will be available for a playback there until May 17, 2018.

PepsiCo's (PEP) Shares Surge on Q1 Earnings & Revenue Beat

2018-04-26 zacks
PepsiCo, Inc. (PEP - Free Report) reported first-quarter 2018 (ending Mar 24) results, with earnings and revenues both beating the Zacks Consensus Estimate. Notably, this is the eighth consecutive quarter of positive earnings surprise. The improvement was mainly attributable to strong performances in its international divisions, propelled by higher revenue growth in developing and emerging markets.

Dr Pepper's (DPS) Q1 Earnings Miss, Revenues Beat Estimates

2018-04-26 zacks
Dr Pepper Snapple Group Inc.’s (DPS - Free Report) first-quarter 2018 earnings missed the Zacks Consensus Estimate while revenues beat the same. Revenues benefited from a growth in sales volumes, favorable product and package mix, segment mix as well as foreign currency translation. Recently, the company announced its acquisition agreement with the well-known coffee maker Keurig Green Mountain, Inc.

Rogers Sugar - Sweeter Than Sugar

2018-04-25 seekingalpha
We believe that the market’s perception of Rogers Sugar as the major player trapped in a limited Canadian sugar industry overshadows management’s efforts to diversify its core business.

Should Dividend Growth'ers Back The Truck Up For Consumer Stocks?

2018-04-25 seekingalpha
My readers know that I've been cautious at best and downright negative at worst on the consumer non-durables space over the past several years. Paying 20+ earnings for companies struggling with both their top- and bottom-lines, despite comparatively attractive yields, hasn't been my idea of dividend or total return alpha.

Coca-Cola (KO) Stock Gains on Q1 Earnings & Revenue Beat

2018-04-24 zacks
The Coca-Cola Company (KO - Free Report) kicked off 2018 on a strong note, beating the Zacks Consensus Estimate on both counts in the first quarter. Apart from a significant rise in soda volumes, the cola giant gained from its growing beverage portfolio and restructuring efforts. Cost-cutting initiatives led by refranchising of its low-margin bottling operations, helped it to come up with better numbers.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 22163N106